BIIB Stock: Price, Earnings History and SEC Filings
Biogen Inc. (BIIB) last traded at $253.62, up 1.59% on the latest session and up 12.3% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $2.62 against an analyst estimate of $2.06, a beat of 27.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BIIB earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 28, 2026 | $2.62 | $2.06 | +27.18% |
| Jun 2026 | Jul 29, 2026 | $3.60 | $3.04 | +18.42% |
| Mar 2026 | Apr 29, 2026 | $3.57 | $2.95 | +21.02% |
| Dec 2025 | Feb 6, 2026 | $1.99 | $1.61 | +23.60% |
BIIB beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How BIIB reacts to earnings
Across its last 8 earnings releases, BIIB moved 4.0% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-28 | Before open | -3.43% |
| 2026-07-29 | Before open | +1.76% |
| 2026-07-01 | After close | +3.04% |
| 2026-04-29 | Before open | +6.00% |
| 2026-04-06 | Before open | -2.82% |
| 2026-02-06 | Before open | +8.53% |
| 2026-01-13 | After close | -5.04% |
| 2025-10-30 | Before open | +1.18% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BIIB financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $9.9B | $1.3B | $2.1B | 13.1% | $8.79 |
| 2024 | $9.7B | $1.6B | $2.7B | 16.9% | $11.18 |
| 2023 | $9.8B | $1.2B | $1.3B | 11.8% | $7.97 |
| 2022 | $10.2B | $3.0B | $1.1B | 29.9% | $20.87 |
| 2021 | $11.0B | $1.6B | $3.4B | 14.2% | $10.40 |
| 2020 | $13.4B | $4.0B | $3.8B | 29.8% | $24.80 |
| 2019 | $14.4B | $5.9B | $6.6B | 41.0% | $31.42 |
| 2018 | $13.5B | $4.4B | $5.4B | 32.9% | $21.58 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BIIB
- 10-Q · Oct 28, 2026
- 8-K · Oct 28, 2026Results of operations, Financial statements and exhibits
- 10-Q · Jul 29, 2026
- 8-K · Jul 29, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 1, 2026Results of operations
- 8-K · Jun 10, 2026Shareholder vote
- 8-K · May 14, 2026Material agreement, Acquisition or disposal completed, New financial obligation
- 10-Q · Apr 29, 2026
- 8-K · Apr 29, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 28, 2026
Insider filing activity
BIIB insiders filed 3 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BIIB news
- What Just Happened To Alnylam Stock?Oct 30, 2026 · trefis.com
- Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC SaysOct 29, 2026 · finance.yahoo.com
- Alphabet downgraded, eBay upgraded: Wall Street's top analyst callsOct 29, 2026 · finance.yahoo.com
- Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026Oct 29, 2026 · finance.yahoo.com
- What to expect from Regeneron’s (REGN) Q3 earningsOct 29, 2026 · finance.yahoo.com
- Biogen (BIIB) Stock Price Tracks Q3 Results Through Loss And Cash FlowOct 29, 2026 · finance.yahoo.com
- Biogen Q3 Earnings Call HighlightsOct 28, 2026 · marketbeat.com
- Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its ReportOct 28, 2026 · finance.yahoo.com
About Biogen Inc.
Biogen Inc. (BIIB) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.